Thrombosis in COVID-19 infection: Role of platelet activation-mediated immunity

Mahin Behzadi Fard 1*, Samaneh Behzadi Fard 2, Shahin Ramazi 3, Amir Atashi 4 and Zahra Eslamifar 1

Abstract

Background: Thrombosis plays an important role in the Coronavirus Disease 2019 (COVID-19) infection-related complications such as acute respiratory distress syndrome and myocardial infarction. Multiple factors such as oxygen demand injuries, endothelial cells injury related to infection, and plaque formation.

Main body: Platelets obtained from the patients may have severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA, showing that the increased activation potential recommends platelet can be hyper-activated in severely ill SARS-CoV-2 cases. Platelets contain multiple receptors that interact with specific ligands. Pathogen’s receptors such as Toll-like receptors (TLRs), NOD-like receptor, C-type lectin receptor family, glycoprotein (GP) such as GPαIIbβ3 and GPIbα which allow pathogens to interact with platelets. Platelet TLRs and NOD2 are involved in platelet activation and thrombosis. Accordingly, TLRs are critical receptors that could recognize various endogenous damage-associated molecular patterns and exogenous pathogen-associated molecular patterns (PAMPs). TLRs are considered as important components in the activation of innate immunity response against pathogenic and non-pathogenic components like damaged tissues. TLRs-1,-2,-4,-6,-7 expression on or within platelets has been reported previously. Various PAMPs were indicated to be capable of binding to platelet-TLRs and inducing both the activation and promotion of downstream proinflammatory signaling cascade.

Conclusion: It is possible that the increased TLRs expression and TLR-mediated platelets activation during COVID-19 may enhance vascular and coronary thrombosis. It may be hypothesized using TLRs antagonist and monoclonal antibody against P-selectin, as the marker of leukocyte recruitment and platelet activation, besides viral therapy provide therapeutic advances in fighting against the thrombosis related complications in COVID-19.

Keywords: SARS-CoV-2, COVID-19, Thrombosis, TLRs, Platelet activation, PAMPs, Proinflammatory cytokines

Introduction

Platelets are key cells in thrombosis, as a physiological process in which vessel damage consequently results in clot formation. However, in pathological situation, these may lead to vessel occlusion, ischemia, and tissue damages [1]. Moreover, endothelial cells injury leads to sub-endothelial exposure, platelet aggregation, and clot formation [2]. Viruses could attach to platelet-plasma or endosomal membrane surface receptors and then active platelets via specific, signaling cascades [3]. Engagement of surface Fc receptors that bind to immunoglobulin-coated virions could also activate platelets [4]. Platelets express pattern recognition receptors (PRRs), including TLR, Nod-like receptor, and C-type lectin receptors that has a critical role in recognition of damage-associated molecular patterns (DAMPs) as well as exogenous pathogen-associated molecular patterns (PAMPs), which is referred as virus associated molecular patterns (VAMPs) in cases of viruses [5–7]. TLRs are critical molecules in the initiation of innate and adaptive immune responses, and may be expressed either on cell surfaces (TLRs-1,2,4,5,6,10) or in the endosome compartment (TLRs-3,7,8,9) [8–11]. These receptors
attachment to DAMP and PAMP can active intracellular pathways such as production of proinflammatory cyto-
kines [12–15]. Platelets endocytose virions, after attach-
ment of TLRs to their released lysosomal ligands i.e., ssRNA, dsRNA, CpG DNA downstream signaling lead to
platelet activation and granule release, expose P-
selectin, and finally form platelet leukocyte aggregates (PLAs) [16].

It is likely that thrombosis due to the activation of the
innate immune system through TLRs could induce some
subsequent vascular occlusive events [17, 18]. Local re-
lease of DAMPs during acute myocardial infarction
(AMI) is known as an event that triggers proinflammatory
TLR activation, which can subsequently aggravate
myocardial injury [19, 20]. Notably, various PAMPs are
capable of inducing platelet activation [21]. Treatment
with pam3CSK4, which is a pharmaceutical agonist of
TLR1/TLR2 ligand, could directly induce platelets acti-
vation; platelet’s adhesion, aggregation, degranulation,
and interaction with leukocytes [12]. Human platelets
express TLRs-1,-2,-4,-6 as well as 7 receptors [22–24].
As well, a recent study showed SARS-CoV-2 spike pro-
ctein could interact with TLRs, especially TLR-4 [25]. It
is possible that alternative platelet activation’s pathways
may promote recurrent thrombosis in COVID-19
patients.

By considering the presence of some TLRs and NOD2
in platelets, these molecules may play roles in platelet
activation and thrombosis in the onset of myocardial in-
farctions during SARS-CoV-2 infection.

Platelet activation and P selectin
P-selectin (CD62P) (formerly known as PADGEM and
GMP140), is an integral protein that acts as a cell adhe-
sion molecule on the surfaces of the activated
endothelial cells as well as the activated platelets to bind
to neutrophil and monocytes [26–28]. The soluble form
of P-selectin lacks the transmembrane domain that ap-
ppears to be produced from alternative splicing of pre
mRNA [29]. Of note, the primary ligand for P-selectin is
P-selectin glycoprotein ligand-1 (PSGL1), which is
expressed on almost all leukocytes. P-selectin leads to
leukocyte rolling and then acts as the first agent for the
leukocyte recruitment [30]. P-selectin is mostly synthe-
sized in endothelial cells and megakaryocyte and then
stored in weibel-palade bodies and α-granules, respect-
ively [31]. Moreover, it plays an essential role in the
initial recruitment of leukocytes to the site of injury during
inflammation. During this process, inflammatory media-
tors such as interleukin-4 (IL-4), tumor necrosis factor-α
(TNF-α), and LPS result in the P-selectin secretion from
endothelial cells. Although LPS and TNF-α increase both
mRNA and protein levels in murine models, they cannot
affect mRNA expression in human endothelial cells,
while IL-4 increases P-selectin mRNA in both of them
[32–34]. It was shown that the P-selectin overexpression
in endothelial cells leads to leukocyte rolling via PSGL-1
and acts as the first agent for the leukocyte recruitment
inflammatory sites [35]. Additionally, P-selectin activ-
ates monocyte to produce tissue factor (TF), which is
the main activator of extrinsic coagulation cascade [36].
It is noteworthy that the P-selectin-mediated leukocyte
recruitment into the lungs during acute respiratory dis-
tress syndrome (ARDS) and infusion of anti P-selectin
(monoclonal antibody) reduce the severity of ARDS [37].
Soluble P-selectin is parallel to platelet’s activation and
thrombosis elevated in ARDS cases compared to control
and also in non-survivors compared to survivors [38,
39].

Due to the high prevalence rate of thrombotic compli-
cations among COVID-19 patients, a possible role has
been suggested for P-selectin in activating intravascular
coagulation [39, 40].

Platelet receptors activation
Platelets included a cytoskeleton and dense tubular sys-
tem, few mitochondria, storage granules; glycogen, δ and
α granules and peroxisomes. The α-granules contain
proteins for the platelets hemostatic functions, such as,
thrombospondin, platelet factor-4, von willebrand factor
(VWF), fibrinogen, P-selectin, CD40 ligand (CD154), β-
thromboglobulin, platelet derived growth factor (PDGF),
FV, GP Ib/IIa, δ granules contain nucleotides (ADP
and ATP), serotonin, histamine, pyrophosphate, and cal-
cium. Upon platelet activation, granules contents are
transfer to platelet membrane or release to extracellular
space to further promote platelet adhesion and activa-
tion [41].

A wide variety of mobile transmembrane receptors
covers the platelet membrane. Many of these receptors
are expressed by other cell types, but some are only
expressed on platelets. It is well known that the major
platelet receptors have a prominent role in the
hemostatic function of platelets, allowing platelets have
specific interactions and functional responses with vas-
cular adhesive proteins. The platelet receptors including
thrombin receptors (PAR-1 and PAR-4), ADP receptors
(P2Y1 and P2Y12), Chemokine receptors (CXCR1 and
 CXCR4), TxA2 receptor, VWF receptor (GP Ib/IIa),
tegrins (αIIbβ3, α5β1, α6β1, αvβ3), Glycoprotein
(GP) Ib/IX/V, Toll-like receptors, proteins belonging to
the immunoglobulin superfamily (GP VI, FcRIIA), P-
selectin, CD63, CD36, P-selectin ligand 1, TNF receptor
type [3, 6, 9, 42]. (Fig. 1).

Platelet receptors and viral infection
Platelets contain multiple receptors that interact with
specific ligands. Pathogen’s receptors such as TLRs,
NOD like receptors, C-type lectin receptor family, FcγRIIA, glycoprotein (GP) αIIbβ3, GP Ibα which allow pathogens to interact with platelets [3, 23, 42, 43]. Innate immune receptors participate in platelet-leukocyte interactions. Pathogens or their products directly or indirectly induce platelet activation. The complex of IgG-pathogen binds to IgG receptor FcγRIIA then leads to pathogen engulfment and reduction. Platelet CD40L expression allows them to interact with different immune cells. In addition, CD40L may be cleaved into a soluble form (sCD40L) that enhances platelet activation, aggregation, and platelet-leukocyte attachment. Platelets can carry and eliminate pathogens, and via the expression of TLRs they can bind bacterial LPS and activate neutrophils, inducing NETs formation. Intact platelet MHC class I molecules are located intracellular but upon activation are expressed and can activate antigen-specific CD8+ T cells. In contrast, the MHC class I molecules on the surface of resting platelets are denatured and lead to CD8+ T cell inhibition. Platelets contain many proinflammatory and anti-inflammatory cytokines and chemokines and, upon activation, can release them to the extracellular space. The culmination of these events makes platelets a main immunomodulatory host (Fig. 2) [6].

Moreover, platelet’s activation during the process of viral exposure by hepatitis virus, adenovirus, Dengue, and HIV-1 was reviewed in a study by Flaujac et al. [44]. Despite the fact that different viruses could activate platelets, its occurrence remained less clear so far. Platelet’s activation after viral exposure can be summarized in the following 3 categories: 1: Viruses may directly bind to surface proteins and then activate platelets via downstream specific signaling cascades [3], 2: Immunoglobulin-coated virions could activate platelets via engagement of surface Fc receptors [4], and 3: TLRs play a role in some viruses (i.e., encephalomyocarditis virus) [45].

**TLRs and platelet activation**

Viral ss-RNA of SARS-COV-2 is sensed by TLR-3, TLR-7, and TLR-8 proteins [46]. Previous studies have shown the internalization and clearance of ssRNA viruses such as influenza and HIV by platelets [13, 22, 47]. TLR7 is
expressed in platelets at both the protein [48] and mRNA level [49, 50]. Platelets can also internalize pathogens (i.e., bacteria and viruses) when an interaction with endosomal TLRs (e.g., TLR-7 and TLR-9) occurs [12, 13, 51]. Upon viral infection, platelets are activated through TLR7 that change their phenotype and induce the formation of platelet-neutrophil aggregates. After the lysosomal degradation of the internalized viral particles, ssRNA genome attaches to endosomal TLR-7. Virus, via ssRNA may mediate platelets’ activation through TLR-7, leading to degranulation, change of phenotype and aggregates with neutrophils. This mechanism is likely to participate in antiviral immunity since TLR-7-depleted mice had an increase in mortality [16, 45, 52]. The activation of TLR-7 pathway leads to platelet’s degranulation of P-selectin, which consequently results in platelet’s activation as well as overexpression of CD40 ligand CD40L/CD154. These aggregates ultimately lead to platelet-neutrophil aggregates and inflammation and thrombocytopenia without promotion of thrombosis [45]. Platelets stimulate with TLR-3 agonists that lead to α-granule-stored factors translocation (P-selectin and CD40L) to cell surface and induce procoagulant responses to traditional agonists such as thrombin [53, 54]. As TLR-7 recognizes viral ss-RNA, it may be important in platelet’s activation related to SARS-CoV-2 infection. Platelet express TLR-4 that recognize PAMPs and DAMPs ligands [55]. DAMPs like histones, high mobility group box 1 (HMGB1) and heat shock proteins (HSPs) that released during host tissue injury or viral infection can bound to neutrophil extracellular traps, (NETs), trigger both prothrombotic and procoagulant platelet-mediated responses, partly by interacting with TLR4 [56–59].

It is possible that TLRs-mediated platelets activation in COVID-19 patients subsequently exaggerates both
vascular and coronary thrombosis and it may also be related to myocardial injury [23, 24].

**Role of platelets in COVID-19 infection**

Platelets maintain the integrity of the alveolar capillaries in normal situation, but in pathologic situation, they may contribute to causing lung injury [60]. In addition, platelet-endothelial interactions and platelet-leukocyte aggregation contribute into the pathogenesis of acute lung injury [61–63]. Moreover, in viral infections, thrombocytopenia, interactions with leukocytes, and platelet’s secretion may lead to the protective or injurious immune effects [64].

In patients with COVID-19, thrombocytopenia rate is estimated at about 5–41.7%, and typically it has a mild form (100–150 x 10^9/L) [65–68]. Additionally, severely thrombocytopenia, which may have an immune mediated source, is rare [69]. It was found that the severe and non-survivors patients have a lower platelet count compared to non-severe and the survivors, respectively [70, 71]. Accordingly, low platelet count in these patients may be due to platelet consumption and associated with the increased risk of mortality; however, it has not been determined as a predictor factor for this disease’s mortality [65, 71]. The patients with a temporal tendency to the decreased platelet count may experience a worsening thrombotic complication and lower nadir platelet counts are related to the increased mortality rate [69, 72].

In viral infections, platelet’s activation may occur either by viral immune complexes or by host inflammatory responses, and the activated platelets are more cleared from circulation by the reticuloendothelial system macrophages [73]. Expression of ACE2, which is the direct receptor of SARS-CoV-2 spike protein on platelets, as well as the induction of platelet’s activation by anti-spike monoclonal antibody were recently reported [74]. A recent report has been shown that circulating platelets obtained from COVID-19 patients had a higher level of surface membranes of P-selectin expression compared to normal controls. Additionally, platelet’s aggregation was greater in patients responding to lower concentrations of platelet agonists [75].

**Toll-like receptors, structures, functions, as well as its specific ligand and main role in thrombosis**

TLRs are type I transmembrane glycoprotein (GP) receptors consisting of (i) 20–27 extracellular leucine-rich repeat (LRR) domains used for the recognition of PAMP/DAMP or VAMP, (ii) a transmembrane domain, and (iii) a cytosolic Toll/interleukin (IL)-1 receptor (TIR) domain used for the activation of downstream cell signaling pathways [76]. The extracellular domains of TLR contain glycan moieties serving as binding sites for ligands. Moreover, TLRs are classified according to their ligands and cellular localizations. Immune cells (including dendritic cells, macrophages, NK cells, T cells, and B cells) as well as non-immune cells (including epithelial and endothelial cells, and fibroblasts) express these receptors [77]. Notably, TLR-1, –2, –4, –5, –6, and 10 are primarily located at the cell surface, whereas TLR3, 7, 8, and 9 are present on the membranes of surrounding intracellular vesicles, including endosomes, lysosomes, and the endoplasmic reticulum that could recognize pathogenic nucleic acids [8, 78].

Furthermore, TLR can be sub-classified based on sequence analysis and three-dimensional structures into three-domain (TLR-1, –2, –4, –6, –10) and single-domain (TLR-3, –5, –7, –8, –9) TLRs [76]. In this regard, the single-domain and three-domain TLRs interact with hydrophilic ligands like nucleic acids, and lipid-containing molecules such as LPS and lipoproteins respectively [79]. Platelet’s activation can up regulate TLR-2, TLR-4, and TLR-9 expressions in these cells [23, 80, 81]. As well, in mice, TLR2 ligands can alter megakaryocyte TLRs expression [82]. Platelets express some functional chemokine receptors such as CCCR1, 3, 4, and CXCR4, which are involved in infection, hemostasis, inflammation, and even in the development of atherosclerosis (Fig. 3) [42].

A recent study revealed that SARS-CoV-2 mRNAs encoding NSP10, E-protein, NSP8, and S2, have strong binding affinities toward intracellular TLR3, TLR7, TLR8, and TLR9, respectively [83]. Additionally, it was shown that SARS-CoV-2 spike protein could interact with TLR4, and TLR-4 activation plays a major role in inflammatory response in COVID-19 infection.

**NOD2 -related platelet activation and thrombosis**

Among the main families of pattern recognition receptors, Toll-like receptors and nucleotide-binding oligomerization domain (NOD)–like receptors are the critical receptors in innate immunity response. NODs are cytoplasmic receptors. NOD1 and NOD2 are the two important NODs, NOD1 and NOD2 contains 1 and 2 caspase recruitment domain respectively [86]. NOD2 is mainly expressed in monocytes, macrophages, dendritic cells, intestinal epithelial cells, and paneth cells whereas NOD1 has a wide distribution. NODs have a major role in innate immune response against infections. In bacterial and viral infections NOD2 through the activation of NF-κB, MAPK and caspase-1 pathways, lead to increase expression of proinflammatory cytokines, including IL-1β, tumor necrosis factor-alpha (TNFα), IL-6, IL-12p40, CC-chemokine ligand 2, IL-8, CCX-chemokine ligand 2 and various antimicrobial agents such as defensins. The NOD2 sensor promotes intestinal pathogen eradication via the chemokine CCL2-dependent recruitment of inflammatory monocytes [87].
NOD2 receptor activation induces platelet production of IL-1β as proinflammatory cytokines [5]. NOD2 as a cytoplasmic viral PRR trigger the activation of interferon-regulatory factor 3 (IRF3) and production of interferon-β (IFN-β). After recognition of a viral ssRNA genome, NOD2 used the adaptor protein mitochondrial antiviral signaling (MAVS) to activate IRF3 and innate immune antiviral response [91]. Similar functions of NOD2 are observed in response to influenza A and parainfluenza viruses [88, 89]. Platelets express NOD2 that potentiates platelet activation and enhances in vivo thrombosis [90]. The crucial role of platelets in thrombosis, hemostasis, and immune response, studies in activation of NOD2 in SARS-CoV-2 infection could showed new insight into the pathogenesis and treatment of inflammation and thrombotic complications in COVID-19 disease.

**Platelets immunomodulatory functions**

Platelet indicates cellular immunomodulatory functions via having interactions with endothelial cells and leukocytes and responses to infection. Accordingly, these responses may consequently enhance vascular inflammation and induce thrombosis [92, 93]. Previous studies have shown that by considering the presence of TLR-1, −2, −4, −6, and TLR-7 at the membrane and intracellular of platelet, their expressions depend on the status of platelet’s activation [22–24]. TLR-1,-6 in infection situation is responsible for generating proinflammatory platelets’ interaction with leukocytes,
including neutrophils, monocytes, eosinophils, and dendritic cells that, as innate immune mediated cells, can accelerate platelet’s aggregation [47]. Circulating platelets contain a functional spliceosome, particularly endogenous pre-mRNAs as well as small nuclear ribonucleoproteins [94–96]. During platelet’s activation, splices introns from interleukin 1-β or tissue factor (TF) pre-mRNAs in platelet cytoplasm can be translated into proteins [97, 98]. In this regard, TF overexpression in platelet and monocyte may be related to thrombosis in COVID-19 [99]. During the platelet activation, growth factor cytokines, chemokines, and molecules such as sCD40L, are released. Platelet is the primary source of sCD40L in circulation that plays a critical role in thrombosis and initiating both innate and adaptive immunities [23, 100]. Additionally, platelets express some functional chemokine receptors such as CCR1, 3, 4, and CXCR4, which are involved in infection, hemostasis, inflammation, and even in the development of atherosclerosis. A previously performed study has shown that sCD62P is increases in ARDS patients and in severe and non-survivors compared with non-severe cases and survivors, respectively [37–39]. Therefore, future discoveries related to the immune-mediated activation platelet are necessary to guide the type of therapies needed to control both thrombosis and coagulopathies, particularly in severely ill COVID-19 patients.

**Inhibitors of TLRs and P-selectin**

TLRs antagonists include monoclonal antibodies, bacterial-derived proteins, natural or synthetic small molecules. TLR3, TLR7, and TLR8 antagonists can be used against viral infections. Among TLRs, TLR4 is a remarkable pattern recognition receptor recognizes multiple PAMPs of bacteria, viruses, and other pathogens and DAMPs from host lytic cells. Several drugs have been demonstrated to have inhibitory effects on the TLR4 pathways. TLR4 antagonist FP7 significantly decreased the cytokine production in response to lethal lipopolysaccharide (LPS) used in the influenza infection [101]. Eritoran and Tak242 as TLR4 antagonists were developed for the treatment of severe sepsis. TAK-242 (Resatorvid) reduce signaling and inflammation by blocks the interaction between TLR4 and the adaptor proteins TIRAP and TRAM [102]. TAK-242 has preclinical success but in clinical investigations the results are not promising. In a phase III trial in managing of severe sepsis, serum cytokine levels suppression of IL-6, IL-8, and TNF-α compared to the placebo group have not been shown [103]. Recently, a novel inhibitory activity of angiotensin II receptor blockers (ARBs), and statins on TLR2 and TLR4 signaling was discovered. Valsartan (from the ARB family) has been demonstrated to decrease proinflammatory cytokine release and infarct size by inhibiting TLR4 signaling. Among statins family, Atorvastatin, Fluvastatin, Simvastatin has all shown an inhibitory effect on the reduction in vascular inflammation and the TLR4 signaling and pathway [104–106]. Eritoran (E5564) and TAK-242 are currently undergoing phase III clinical trials, especially for severe sepsis. In septic cases with in the high-dose treatment of eritoran a 12% reduction in the mortality rate compared to placebo was demonstrated [107]. Eritoran blocked DAMP accumulation and attenuated influenza virus-induced acute lung injury [108].

Anti P-selectin monoclonal antibodies or P-selectin antagonist reduces the risk of inflammation and thrombosis [109]. Inclacumab a novel and recombinant monoclonal antibody against P-selectin, block the P-selectin-PSGL-1 mediated cell adhesion. Inclacumab is a human IgG4 monoclonal antibody has anti-cell adhesion effects and the potential of anti-inflammatory, antithrombotic, and antiatherogenic properties [110–112]. Recently, cri-zanlizumab, a human IgG2 anti-P-selectin antibody, approved by FDA. Crizanlizumab reduce vaso-occlusive crises (VOCs) in sickle cell disease patients [113]. These P-selectin antagonists may have benefits to inhibit of platelet-leukocyte-endothelial interactions in COVID-19 patients and reduce the thrombosis complications induced by SARS-COV2 infection.

**Conclusion**

Severe SARS-CoV-2 infection mostly presents with coagulation abnormalities, pulmonary microvascular thrombosis, and severe inflammatory response [114]. Thrombosis complications are common among critically ill COVID-19 patients, and these also increase the risk of some life-threatening complications such as myocardial infarction and ARDS [40, 41]. Although the mechanisms of thrombosis in SARS-CoV-2 infection are still unclear, platelet’s activation and inflammatory responses may contribute in this process [42]. TLRs could bind to the specific ligands and then result in the activation of the inflammatory cascades. As well, platelet can be activated by TLRs, and in addition, inflammatory mediators such as LPS and TNF-α may induce P-selectin expression [16, 84]. P-selectin, as a platelet’s activation marker, plays central roles in leukocyte recruitment and expression of TF by monocyte, which is the activator of extrinsic coagulation cascade [43]. Both platelet’s activation and aggregation play critical roles in the pathogenesis of tissue damages such as acute myocardial infarction (AMI) and myocardial ischemia injury [115, 116]. Additionally, local release of DAMPs during the process of AMI is known to trigger proinflammatory TLRs activation, which consequently leads to the aggravation of myocardial injury [19, 20]. It is possible that the alternative platelet activation pathways, which are not targeted
by currently available anti-platelet agents, may promote recurrent thrombosis in these settings [117].

SARS-CoV-2-spike protein attachment to ACE2 on endothelial cells, platelets, and other target cells, triggers the pathogenesis of COVID-19 infection [25, 83]. Previous studies have found that the spike protein could bind to extracellular domains of TLRs, including TLR-1,-4,-6 [25]. Moreover, it has been proposed that the spike protein have a strong affinity with TLR4. Accordingly, TLR4 is mainly present at the surface cell membrane and it recognizes viral proteins before their entrance into the cell and also into the endosomal membrane [118]. TLR4 signaling is important in initiating inflammatory responses, and its overexpression can also lead to hyper inflammation reactions [119–121]. Regarding the fact that platelet could express TLR-4, it may play significant roles in both platelet’s activation and thrombosis. As well, Platelet overexpression of P-selectin in severe SARS-CoV-2 patients suggests a central role of platelet’s activation as a part of the pathogenic mechanism of COVID-19 leading to the production of pulmonary thrombi. So, the administration of anti P-selectin antibody like Crizanlizumab or inclacumab may be helpful for the severe cases. In this regard, a rapid investigation is required to determine the pathways that mostly contribute to platelet’s activation, because these may be important in reducing the rates of morbidity and mortality caused by COVID-19 infection. Among the alternative pathways, TLRs related thrombosis may play a more critical role in COVID-19 complex pathophysiology. In this regard, further studies are required to determine the role of TLRs in the mechanisms of thrombosis and coagulopathies associated with COVID-19 infection. In addition, the administrations of anti-P selectin monoclonal antibody and TLRs antagonist may reduce the cytokine storm, thrombosis, and mortality in COVID-19 patients. More studies are needed to investigate the clinical significance of both TLRs upregulation and antagonist in COVID-19-related thrombosis.

**Abbreviations**

SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; COVID-19: coronavirus disease; TLRs: toll-like receptors; PAMPs: pathogen-associated molecular patterns; TF: tissue factor

**Acknowledgements**

Not applicable.

**Authors’ contributions**

All Authors contributed to write the paper and approved the final manuscript.

**Funding**

Not applicable.

**Availability of data and materials**

Not applicable.

**Declarations**

**Ethics approval and consent to participate**

As the current study was a review, there was no ethics committee to approve the study.

**Consent for publication**

All authors have consent to publication.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1Dezful university of medical sciences, Dezful, Iran. 2Kerman university of medical sciences, Kerman, Iran. 3Department of biophysics, faculty of biological sciences, Tarbiat Modares University, Tehran, Iran. 4Stem cell and tissue engineering research center, Shahroud university of medical sciences, Shahroud, Iran.

Received: 18 March 2021 Accepted: 10 August 2021

**Published online:** 23 August 2021

**References**

1. Lin E, Freedman JE, Beaulieu LM. Innate immunity and toll-like receptor antagonists: a potential role in the treatment of cardiovascular diseases. Cardiovasc Ther. 2009;27(2):117–23. https://doi.org/10.1111/j.1755-9292.2009.00077.x.

2. Seyoum M, Enawgaw B, Melku M. Human blood platelets and viruses: defense mechanism and role in the removal of viral pathogens. Thromb J. 2018;16(1):1–6.

3. Chaipan C, Soilleux EJ, Simpson P, Hofmann H, Gramberg T, Marzi A, et al. DC-SIGN and CLEC-2 mediate human immunodeficiency virus type 1 capture by platelets. J Virol. 2006;80(18):9591–60. https://doi.org/10.1128/JVI.00316-06.

4. Cloutier N, Allaeyes I, Marcoux G, Machlus KR, Mailhot B, Zufferey A, et al. Platelets release pathogenic serotonin and return to circulation after immune complex-mediated sequestration. Proc Natl Acad Sci. 2018;115(7):E1550–E9. https://doi.org/10.1073/pnas.1720053115.

5. Zhang S, Zhang S, Hu L, Zhai L, Xue R, Ye J, et al. Nucleotide-binding oligomerization domain 2 receptor is expressed in platelets and enhances platelet activation and thrombosis. Circulation. 2015;131(13):1160–70. https://doi.org/10.1161/CIRCULATIONAHA.114.013743.

6. Dib PB, Quirino-Teixeira AC, Menj LB, Pinheiro MM, Rozini SV, Andrade FB, et al. Innate immune receptors in platelets and platelet-leukocyte interactions. J Leukoc Biol. 2020;108(4):1157–82. https://doi.org/10.1002/JLB.4MR0620-701R.

7. Clemetson KJ, Clemetson JM. Platelet Receptors. In: Platelet receptors. 2019. p. 169–92.

8. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003;21(1):335–76. https://doi.org/10.1146/annurev.immunol.21.120601.141126.

9. Blasius AL, Beutler B. Intracellular toll-like receptors. Immunity. 2010;32(3):305–15. https://doi.org/10.1016/j.immuni.2010.03.012.

10. Lien E, Ingalls RR. Toll-like receptors. Crit Care Med. 2002;30(1):S1–S11. https://doi.org/10.1097/00003495-200201000-00001.

11. More sco EMY, LaVine D, Beutler B. Toll-like receptors. Curr Biol. 2011;21(13):R488–R93. https://doi.org/10.1016/j.cub.2011.05.039.

12. Blair P, Rex S, Vitteva O, Beaulieu L, Tannirvedi K, Chakrabarti S, et al. Stimulation of toll-like receptor 2 in human platelets induces a thromboinflammatory response through activation of phosphoinositide 3-kinase. Circ Res. 2009;104(3):346–54. https://doi.org/10.1161/CIRCRESAHA.108.185785.

13. Riviardenya L, Caresta A, Etalain J, Pozner RG, Fonevaiva C, Negrotto S, et al. Regulation of platelet responses triggered by toll-like receptor 2 and 4 ligands is another non-genomic role of nuclear factor-kappaB. Thromb Res. 2014;133(2):225–3. https://doi.org/10.1016/j.thromres.2013.11.028.

14. Zhang G, Han J, Welch EJ, Richard DY, Voyno-Yasenetskaya TA, Malik AB, et al. Lipopolysaccharide stimulates platelet secretion and potentiates platelet aggregation via TLR4/MyD88 and the cGMP-dependent protein kinase pathway. J Immunol. 2009;182(12):7997–8004. https://doi.org/10.4049/jimmunol.0802884.
15. Wu J, Chen ZJ. Innate immune sensing and signaling of cytosolic nucleic acids. Annu Rev Immunol. 2014;32(1):461–88. https://doi.org/10.1146/annurev-immunol-031713-120156.

16. Banerjee M, Huang Y, Joshi S, Popa GJ, Mendenhall MD, Wang QJ, et al. Platelets endocytose viral particles and are activated via TLR (toll-like receptor) signaling. Arterioscler Thromb Vasc Biol. 2020;40(7):1635–50. https://doi.org/10.1161/ATVBAHA.120.314180.

17. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med. 2004;351(25):2611–8. https://doi.org/10.1056/NEJMoa041747.

18. Jayachandran M, Brunn GJ, Karmicki K, Miller RS, GW, Miller VM. In vivo effects of lipopolysaccharide and TLR4 on platelet production and activity: implications for thrombotic risk. J Appl Physiol. 2007;101(2):429–33. https://doi.org/10.1152/japplphysiol.01576.2005.

19. Arumugam TV, Okun E, Tang S-C, Thundil J, Taylor SM. Toll-like receptors in ischaemia-reperfusion injury. Shock. 2009;32(1):14–16. https://doi.org/10.1097/SHK.0b013e3181936e33.

20. Shimamoto A, Chong AJ, Yada M, Shomura S, Takayama H, Fleisig AJ, et al. Inhibition of Toll-like receptor 4 with eritoran attenuates myocardial ischemia-reperfusion injury. Circulation. 2006;114(18):2707–14.

21. Kreutz R, Bleden K, Tantry U, Gurbel P. Viral respiratory tract infections and rates of myocardial infarction and stroke during viral illness. J Thromb Haemost. 2005;3(9):2108–15. https://doi.org/10.1111/j.1538-7836.2005.01744.x.

22. Shiraki R, Inoue N, Kawasaki S, Takei A, Kadotani M, Ohnishi Y, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thorax Res. 2020;191:145–7. https://doi.org/10.1016/j.676.2020.04.013.

23. Kausot A, Hoylaerts MF. Platelet receptors. Antithrombot Agents. 2012;3:53–7. https://doi.org/10.1177/178432901245436.

24. Clemetson KJ, Clemetson JM, Proudfoot AE, Power CA, Bagnoli M, Wells TN. Functional expression of CCR1, CCR3, CCR4, and CXCR4 chemokine receptors on human platelets. Blood J Am Soc Hem. 2000;96(13):4046–54.

25. Boulouk S, Masé JM, Beint L, Dubart-Kupperschmitt A, Cramer E. Lentinus degradation and DC-SIGN expression by human platelets and megakaryocytes. J Thromb Haemost. 2006;4(2):426–35. https://doi.org/10.1111/j.1538-7836.2006.01749.x.

26. Flajac C, Boulour S, Cramer-Bordet E. Platelets and viruses: an ambivalent relationship. Cell Mol Life Sci. 2010;67(4):545–56. https://doi.org/10.1007/s00018-009-0209-x.

27. Kroukova M, Vitsoe O, MacKay CR, Beaulieu LM, Benjamin EJ, Mick E, et al. Platelet-TLR7 mediates host survival and platelet count during viral infection in the absence of platelet-dependent thrombosis. Blood J Am Soc Hem. 2014;124(5):791–802.

28. Azkur AK, Akdis C, Azkur D, Sokolowska M, van de Veen W, Brüggen MC, et al. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy. 2020;75(7):1564–81. https://doi.org/10.1111/all.14364.

29. Koenen RR. The prowess of platelets in immunity and inflammation. Thromb Haemost. 2016;116(10):605–12.

30. Panagris H, Ma Y, Hong L, Gao D, West XZ, Solomons RG, et al. Engagement of platelet toll-like receptor 9 by novel endogenous ligands promotes platelet hyperreactivity and thrombosis. Circ Res. 2010;112(13):1103–12. https://doi.org/10.1161/circresaha.112.274241.

31. Kroukova M, Mick E, Mikhailov E, Benjamin EJ, Tanzerlverdi K, Frederick J. Sex differences in platelet toll-like receptors and their association with cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 2015;35(4):1030–7. https://doi.org/10.1161/ATVBAHA.114.304954.

32. Rex S, Beaulieu LW, Perlman DH, Vitsoe O, Blair PS, McComb ME, et al. Immune versus thrombotic stimulation of platelets differentially regulates signaling pathways, intracellular protein-protein interactions, and α-granule release. Thromb Haemost. 2009;102(7):97–110. https://doi.org/10.1111/j.1464-5410.2009.03013.x.

33. O'Neill LA, Golenbock D, Bowie AG. The history of toll-like receptors—defining innate immunity. Nat Rev Immunol. 2013;13(6):453–60. https://doi.org/10.1038/nri3466.

34. Scherlinger M, Sisirak V, Richez C, Lazaaro E, Dufau P, Blanco P. New insights on platelets and platelet-derived microparticles in systemic lupus erythematosus. Curr Rheumatol Rep. 2017;19(8):1–10.

35. D'Am PI, Etulain J, Raudenova L, Lapponi MJ, Centurion M, Cheng K, et al. Expression and functionality of toll-like receptor 3 in the megakaryocytic lineage. J Thromb Haemost. 2015;13(5):839–50. https://doi.org/10.1111/j.1538-7836.2014.04282.

36. Anabel A-S, Eduardo P-C, Antonio H-CP, Carlos S-M, Juana N-M, Honorio T-A, et al. Human platelets express toll-like receptor 3 and respond to poly I:C: implications for transcriptional regulation in endothelial cells. J Biol Chem. 1998;273(16):10058–67. https://doi.org/10.1074/jbc.273.16.10058.

37. Mulligan MS, Polley MJ, Bayer RJ, Nunn MF, Paulson J, Ward PA. Neutrophil-dependent acute lung injury. Requirement for P-selectin (GMP-140). J Clin Invest. 1992;90(4):1600–7. https://doi.org/10.1172/JCI16029.

38. Agnati C, Bordini V, Sacchi A, Petrosillo N, Ricciardi C, Del Nonno F, et al. Elevated P-Selectin in severe Covid-19: considerations for therapeutic options. Med J Hematol Infectious Diseases. 2021;13(1).

39. Neri T, Nieri D, Cel A. P-selectin blockade in COVID-19 related ARDS. Am J Phys Lung Cell Mol Phys. 2020;38(6):L1237–8. https://doi.org/10.1152/ajplung.00202.2020.

40. Klok F, Kruijp M, Van der Meer N, Arbous M, Gommers D, Kant K, et al. Elevated P-selectin in severe Covid-19: considerations for therapeutic options. Med J Hematol Infectious Diseases. 2021;13(1).

41. Mogensen TH, Paludan SR. Reading the viral signature by toll-like receptors and other pattern recognition receptors. J Mol Med. 2005;83(3):189–92. https://doi.org/10.1007/s00109-004-0620-6.
104. Gao W, Xiong Y, Li Q, Yang H. Inhibition of toll-like receptor signaling as a promising therapy for inflammatory diseases: a journey from molecular to nano therapeutics. Front Physiol. 2017;8:508. https://doi.org/10.3389/fphys.2017.00508.

105. Koushki K, Shahtalizadeh SK, Mashayekhi K, Sadeghi M, Zayeri ZD, Tabar MY, et al. Anti-inflammatory action of statins in cardiovascular disease: the role of inflammasome and toll-like receptor pathways. Clin Rev Allergy Immunol. 2021;60(2):175–99. https://doi.org/10.1007/s12016-020-08791-9.

106. Yang M, Diao Z, Wang Z, Yan G, Zhao G, Zheng M, et al. Pravastatin alleviates lipopolysaccharide-induced placental TLR4 over-activation and promotes uterine arteriole remodeling without impairing rat fetal development. J Biomed Res. 2018;32(4):289–97. https://doi.org/10.7555/JBR.32.20180039.

107. Wickelgren I. Targeting the tolls. American Association for the Advancement of Science; 2006.

108. Shirey KA, Lai W, Lipsky M, Mistry P, Pletneva LM, et al. The TLR4 antagonist Eritoran protects mice from lethal influenza infection. Nature. 2013;497(7450):498–502. https://doi.org/10.1038/nature12118.

109. Myers DO, Schaub R, Wroblewski SK, Londy FJ, Fox BA, Chapman AM, et al. P-selectin antagonism causes dose-dependent venous thrombosis inhibition. Thromb Haemost. 2001;85(3):423–9.

110. Schmitt C, Abt M, Giorgio C, Kling D, Jamois C, Schick E, et al. First-in-man study with inclacumab, a human monoclonal antibody against P-selectin. J Cardiovasc Pharmacol. 2015;65(6):611–9. https://doi.org/10.1097/FJC.0000000000000233.

111. Tardif JC, Tanguay JF, Wright SR, Duchatelie V, Petroni T, Grégoire JC, et al. Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non-ST-segment elevation myocardial infarction: results of the SELECT-ACS trial. J Am Coll Cardiol. 2013;61(20):2048–55. https://doi.org/10.1016/j.jacc.2013.03.003.

112. Geng X, Mihaila R, Yuan Y, Strutt S, Benz J, Tang T, et al., editors. Inclacumab, a fully human anti-P-selectin antibody, directly binds to PSGL-1 binding region and demonstrates robust and durable inhibition of cell adhesion. Blood; 2020: AMER SOC HEMATOLOGY 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA.

113. Malea P, Caughey M, Robinson L, Desai PC, Jones S, Nouraie M, et al. Risk factors for mortality in adult patients with sickle cell disease: a meta-analysis of studies in North America and Europe. Haematologica. 2017;102(4):626.

114. Connors JM, Levy JH. Thromboinflammation and the hypercoagulability of COVID-19. J Thromb Haemost. 2020;18(7):1559–61. https://doi.org/10.1111/jth.14849.

115. Gavaz M, Neumann F-J, Ott I, Schiessler A, Schömig A. Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation. 1996;93(2):229–37. https://doi.org/10.1161/01.CIR.93.2.229.

116. Xu Y, Hua Y, Toufekeissian M-C, Ramos SI, Ma Y, Tejani AD, et al. Activated platelets contribute importantly to myocardial reperfusion injury. Am J Phys Heart Circ Phys. 2006;290(2):H692–H9. https://doi.org/10.1152/ajpheart.00634.2005.

117. Hally KE, La Flamme AC, Larsen PD, Harding SA. Platelet toll-like receptor (TLR) expression and TLR-mediated platelet activation in acute myocardial infarction. Thromb Res. 2017;158:8–15. https://doi.org/10.1016/j.thromres.2017.07.031.

118. Kuzmich NN, Sivak KV, Chubarev VN, Porozov YB, Savateeva-Lyubimova TN, Peri F. TLR4 signaling pathway modulators as potential therapeutics in inflammation and sepsis. Vaccines. 2017;5(4):34. https://doi.org/10.3390/vaccines5040034.

119. Molteni M, Gemma S, Rossetti C. The role of toll-like receptor 4 in infectious and noninfectious inflammation. Mediat Inflamm. 2016;2016:1–9. https://doi.org/10.1155/2016/6978936.

120. Patra MC, Shah M, Choi S, editors. Toll-like receptor-induced cytokines as immunotherapeutic targets in cancers and autoimmune diseases. Seminars in cancer biology; 2020: Elsevier.

121. Boshan MH, Tambo A, Pace NP. The role of TLR2, TLR4, and TLR9 in the pathogenesis of atherosclerosis. Int J Inflamm. 2016;2016:1–11. https://doi.org/10.1155/2016/15328832.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.